|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
08.03.26 - 19:03
|
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 (GlobeNewswire EN)
|
|
|
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (FOS), on Monday, March 9, 2026....
|
|
|
07.03.26 - 23:18
|
A Record-Setting Saturday as Broad Arrow Closes $107M+ $Amelia Concours Auction with $6,605,000 Lamborghini Miura SV (GlobeNewswire EN)
|
|
|
Broad Arrow sees enthusiastic bidding from start to finish during second and final day of 2026 Amelia Concours Auction | Saturday led by 1972 Lamborghini Miura P400 SV at $6,605,000, a landslide new world for a Miura at auction | Two-day sale total currently sits in excess of $107 million, Broad Arrow's most successful auction to date | Strong prices and additional records achieved across all segments of the market, most notably for Ferraris and for Americana offered from respected private collections | Complete results will be available at broadarrowauctions.com in coming days Broad Arrow sees enthusiastic bidding from start to finish during second and final day of 2026 Amelia Concours Auction | Saturday led by 1972 Lamborghini Miura P400 SV at $6,605,000, a landslide new world for a Miura at auction | Two-day sale total currently sits in excess of $107 million, Broad Arrow's most successful auction to date | Strong prices and additional records achieved across all segments of the market, most notably ...
|
|
|
|
|
|
|
07.03.26 - 03:21
|
NEWS FLASH: Broad Arrow Smashes World Records with Collection of Unobtanium Supercars on Day One of Amelia Concours Auction (GlobeNewswire EN)
|
|
|
Nero 2003 Ferrari Enzo Leads Collection at $15,185,000 | 1988 Porsche 959 Sport Achieves New Record for the Model at $5,505,000 | 2021 Ferrari Monza SP2 Sets New Benchmark at $4,955,000 | 2017 Ferrari F12tdf Reaches New Heights at $4,185,000 | 2015 Porsche 918 Spyder Sells for World Record Price at $2,975,000 | Outside the Collection, Paint-to-Sample 2005 Porsche Carrera GT Doubles Previous Record at $6,715,000 Nero 2003 Ferrari Enzo Leads Collection at $15,185,000 | 1988 Porsche 959 Sport Achieves New Record for the Model at $5,505,000 | 2021 Ferrari Monza SP2 Sets New Benchmark at $4,955,000 | 2017 Ferrari F12tdf Reaches New Heights at $4,185,000 | 2015 Porsche 918 Spyder Sells for World Record Price at $2,975,000 | Outside the Collection, Paint-to-Sample 2005 Porsche Carrera GT Doubles Previous Record at $6,715,000...
|
|
|
07.03.26 - 01:21
|
AMC Networks Announces Expiration of Consent Solicitation to Amend its 10.50% Senior Secured Notes due 2032 (GlobeNewswire EN)
|
|
|
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) announced today the expiration and results of the previously announced and extended consent solicitation (the “Consent Solicitation”) soliciting consents (“Consents”) from the holders of its existing 10.50% Senior Secured Notes due 2032 (the “Notes”) to amend the indenture governing the Notes to (1) amend the covenant that limits restricted payments in order to permit buybacks, purchases, redemptions, retirements or other acquisitions of AMC Networks Inc.'s equity interests in an aggregate amount not to exceed $50,000,000; (2) revise the covenant that limits transfers or licenses of certain trademarks to unrestricted subsidiaries to only permit transfers of non-exclusive licenses; and (3) restrict investments in unrestricted subsidiaries made pursuant to the definition of “Permitted Investments” to certain specified clauses in such definition (the “Amendments”)....
|
|
|
07.03.26 - 01:21
|
AMC Networks Announces Early Tender Results of Any and All Exchange Offer and Consent Solicitation for its 10.25% Senior Secured Notes due 2029 (GlobeNewswire EN)
|
|
|
NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- AMC Networks Inc. (“AMC Networks” or the “Company”) (Nasdaq: AMCX) today announced the early participation and consent results in connection with its previously announced (i) exchange offer (the “Exchange Offer”) to Eligible Holders (as defined below) to exchange any and all of its outstanding 10.25% Senior Secured Notes due 2029 (the “Old Notes”) for its newly-issued 10.50% Senior Secured Notes due 2032 (the “New Notes”), and (ii) the solicitation of consents (the “Consent Solicitation”) from holders of the Old Notes with respect to the amendment (the “Proposed Amendment”) to the indenture governing the Old Notes (the “Old Notes Indenture”) described below, on the terms and subject to the conditions set forth in a Confidential Offering Memorandum and Consent Solicitation Statement, dated as of February 23, 2026 (the “Offering Memorandum”). Capitalized terms not defined herein shall have the respective meanings ascribed to ...
|
|
|
07.03.26 - 01:03
|
AIM ImmunoTech Announces Closing of its Rights Offering (GlobeNewswire EN)
|
|
|
OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of approximately $1.8 million....
|
|
|
|
|
|
|
|
|
|
|
06.03.26 - 23:36
|
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
BOSTON, March 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that, effective February 2, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 367,500 shares of its common stock and 60,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan....
|
|